Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

NCT04220944 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Hepatic Carcinoma

Interventions

DRUG: Sintilimab
PROCEDURE: Microwave Ablation
PROCEDURE: TACE

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]